| Old Articles: <Older 6161-6170 Newer> |
 |
The Motley Fool January 28, 2010 Brian Orelli |
Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say?  |
The Motley Fool January 28, 2010 Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.  |
The Motley Fool January 28, 2010 Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.  |
The Motley Fool January 28, 2010 Brian Orelli |
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends.  |
The Motley Fool January 28, 2010 Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.  |
The Motley Fool January 27, 2010 Brian Orelli |
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.  |
The Motley Fool January 27, 2010 Brian Orelli |
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note.  |
The Motley Fool January 27, 2010 Brian Orelli |
The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs.  |
The Motley Fool January 26, 2010 Brian Orelli |
Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010.  |
The Motley Fool January 26, 2010 Brian Orelli |
Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug.  |
| <Older 6161-6170 Newer> Return to current articles. |